BLACKSBURG, Va.--(BUSINESS WIRE)--NImmune Biopharma ('NImmune”), a late-clinical-stage precision immunology biopharmaceutical company that develops novel best-in-class biomarker-driven immunoregulatory therapeutics, today announced a research collaboration with BioTherapeutics, Inc. (“BioTherapeutics”), a clinical-stage biotech company that combines advanced computational modeling with translational and clinical experimentation to accelerate the development of novel products.

弗吉尼亚州布莱克斯堡（商业新闻短讯）--NImmune Biopharma（“NImmune”）是一家临床晚期精密免疫学生物制药公司，开发新型一流的生物标志物驱动的免疫调节疗法，今天宣布与BioTherapeutics，Inc.（“BioTherapeutics”）进行研究合作，这是一家临床阶段的生物技术公司，将先进的计算建模与翻译和临床实验相结合，以加速新产品的开发。

The collaboration strengthens NImmune’s precision immunology capabilities by providing access to BioTherapeutics’ preclinical services and regulatory capabilities for product testing, mechanism of action validation studies, and development of animal and computational models of inflammatory and autoimmune disease.

。

NImmune will also gain access to BioTherapeutics’ proprietary animal models of disease, including its unique pig models of IBD, PK/PD analysis capabilities and expert regulatory infrastructure..

NImmune还将获得BioTherapeutics专有的疾病动物模型，包括其独特的IBD猪模型，PK/PD分析能力和专家监管基础设施。。

Dr. Raquel Hontecillas, BioTherapeutics Chief Scientific Officer, stated, “We are excited to collaborate across teams in support of the development of much-needed therapeutics by providing our highly sophisticated computational and preclinical services, including our proprietary efficacy animal models of autoimmune and inflammatory disease.

生物治疗学首席科学官Raquel Hontecillas博士表示：“我们很高兴能够通过提供高度复杂的计算和临床前服务，包括我们专有的自身免疫和炎症性疾病的功效动物模型，跨团队合作，支持急需的治疗剂的开发。

The unique drug development ecosystem created here in Blacksburg enables and equips our organizations to develop safer and more effective therapeutics at an increasingly efficient and accelerated pace.”.

在布莱克斯堡创建的独特的药物开发生态系统使我们的组织能够以越来越高效和加速的速度开发更安全和更有效的治疗方法。”。

NImmune’s partnership with BioTherapeutics complements an existing R&D partnership with NIMML Institute, creating a unique scientific innovation ecosystem for transdisciplinary teams to collaborate from discovery through various development phases. This ecosystem demonstrated significant clinical and commercial success this year with BioTherapeutics and NIMML Institute having enabled the development of NX-13 and its acquisition by AbbVie, Inc.

NImmune与生物治疗学的合作关系补充了与NIMML研究所现有的研发合作关系，为跨学科团队创造了一个独特的科学创新生态系统，从发现到各个开发阶段进行合作。这一生态系统今年取得了重大的临床和商业成功，生物治疗学和NIMML研究所开发了NX-13并被AbbVie，Inc.收购。

(NYSE: ABBV)..

（纽约证券交易所：ABBV）。。

'The collaboration with BioTherapeutics is a crucial extension of NImmune's innovative R&D ecosystem that is enabling our team to create safer and more effective immunoregulatory therapeutics that address the unmet clinical needs of patients with inflammatory and autoimmune diseases,” said Dr. Josep Bassaganya-Riera, Founder & CEO of NImmune.

NImmune创始人兼首席执行官Josep Bassaganya Riera博士说：“与生物治疗学的合作是NImmune创新研发生态系统的重要延伸，使我们的团队能够创造更安全，更有效的免疫调节疗法，以满足炎症和自身免疫性疾病患者未满足的临床需求。”。

“Through NImmune’s strategic partnerships with both the NIMML Institute and BioTherapeutics, we have created a best-in-class scientific ecosystem capable of accelerating the pipeline—from A.I.-enabled target discovery and validation using the TITAN-X platform to preclinical animal modeling to clinical testing and ultimately commercialization.

“通过NImmune与NIMML研究所和生物治疗学的战略合作伙伴关系，我们创造了一个一流的科学生态系统，能够加速从使用TITAN-X平台的人工智能目标发现和验证到临床前动物建模到临床测试和最终商业化的过程。

The regulatory infrastructure, preclinical resources, and leading proprietary models of disease and pathology developed and honed at BioTherapeutics allow us to focus NImmune’s organizational energy squarely on advancing clinical development of our immunoregulatory therapeutic pipeline.'.

生物治疗学开发和磨练的监管基础设施，临床前资源以及领先的疾病和病理学专有模型使我们能够将尼姆的组织精力完全集中在推进我们免疫调节治疗管道的临床开发上。”。

“We’re proud to enter this strategic partnership, which combines BioTherapeutics’ validated models of inflammatory and autoimmune diseases with our expertise in rapidly translating fundamental scientific discoveries in immunology into safer and more effective medicines for patients with immune-mediated diseases such as ulcerative colitis, Crohn’s disease, psoriasis, rheumatoid arthritis, asthma, and systemic lupus erythematosus,” continued Dr.

“我们很自豪能加入这一战略合作伙伴关系，它将生物治疗学验证的炎症和自身免疫性疾病模型与我们的专业知识相结合，快速将免疫学的基本科学发现转化为更安全，更有效的药物，用于治疗免疫介导的疾病，如溃疡性结肠炎，克罗恩病，牛皮癣，类风湿性关节炎，哮喘和系统性红斑狼疮，”博士继续说道。

Bassaganya-Riera. “We look forward to the ongoing collaboration between BioTherapeutics and NImmune, as well as the NIMML Institute, to significantly accelerate the clinical development of our high-conviction drug candidates.”.

巴萨加尼亚·里埃拉。“我们期待着生物治疗药物与尼姆恩以及NIMML研究所之间的持续合作，以显着加速我们高度自信的候选药物的临床开发。”。

About NImmune Biopharma

关于NImmune生物制药

NImmune is a late-stage precision immunology biopharmaceutical company that develops novel best-in-class biomarker-driven immunoregulatory therapeutics. Underpinned by a discovery platform that utilizes advanced computational modeling, A.I. and bioinformatics coupled with biomedical research capabilities to pioneer innovation in immunoregulatory drug development, NImmune’s business model enables the rapid and capital-efficient clinical development of high conviction drug candidates into New Drug Application (NDA) filing and commercialization.

。NImmune的商业模式以一个发现平台为基础，该平台利用先进的计算建模，人工智能和生物信息学以及生物医学研究能力来开创免疫调节药物开发的创新，使高信念候选药物的快速和资本高效的临床开发成为新药申请（NDA）申请和商业化。

The lead product candidate from NImmune’s discovery platform is omilancor, a wholly-owned Phase 3-ready oral, once-daily, gut-restricted, first-in-class therapeutic targeting LANCL2 for Ulcerative Colitis and Crohn’s disease with registration-directed pivotal clinical trials planned for 2H’23. Phase 2 proof-of-concept data for omilancor show potential best in class efficacy and safety.

NImmune发现平台的主要候选产品是omilancor，这是一家全资拥有的3期口服，每日一次，肠道受限，一流的针对溃疡性结肠炎和克罗恩病的LANCL2治疗药物，计划于2小时进行注册指导的关键临床试验23。omilancor的第二阶段概念验证数据显示出潜在的同类最佳疗效和安全性。

For more information, please visit www.NIMMUNEBIO.COM or contact media@nimmunebio.com..

有关更多信息，请访问www.NIMMUNEBIO.COM或联系media@nimmunebio.com..

About BioTherapeutics, Inc.

关于BioTherapeutics，Inc。

BioTherapeutics, Inc., a clinical-stage biotech company that synergistically combines the power of advanced computational modeling with translational and clinical experimentation to accelerate the development of novel products for precision medicine and health. The company is headquartered in Blacksburg, VA.

BioTherapeutics，Inc.，一家临床阶段的生物技术公司，将先进的计算建模与翻译和临床实验的力量协同结合，以加速精密医学和健康新产品的开发。。

For more information, please visit www.biotherapeuticsinc.com..

有关更多信息，请访问www.biotherapeuticsinc.com。。